Skip to main content

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.

A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 192
  • Page 193
  • Page 194
  • Page 195
  • Page 196
  • Page 197
  • Page 198
  • Page 199
  • Page 200
  • …
  • Next page Next
  • Last page Last
Subscribe to